

**STICHTING DUCHENNE DATA FOUNDATION
AT BERGEN OP ZOOM**

Annual Report 2021

November 21, 2023

CONTENTS

Pagina

AUDITOR'S REPORT

1	Engagement	2
2	Accountant's compilation report	2
3	Results	3
4	Financial position	4

MANAGEMENT BOARD REPORT

1	Management board report	6
---	-------------------------	---

FINANCIAL STATEMENTS

1	Balance sheet as at December 31, 2021	14
2	Statement of the financial activities over 2021	16
3	Notes to the financial statements	17
4	Notes to the balance sheet as of December 31, 2021	19
5	Notes to the statement of financial activities 2021	22

OTHER INFORMATION

1	Audit	25
2	Recognition of the loss for 2021	25

AUDITOR'S REPORT

To the management of
Stichting Duchenne Data Foundation
Warmoesdreef 10
4614 HC Bergen op Zoom

<i>Reference</i>	<i>Processed by</i>	<i>Date</i>
11201	HB-IL	November 21, 2023

Dear members of the Executive Board,

We hereby send you the report regarding the financial statements for the year 2021 of your company.

1 ENGAGEMENT

In accordance with your instructions we have compiled the annual account 2021 of your company, including the balance sheet with counts of € 469,677 and the statement of financial activities with a negative result of € 5,417.

2 ACCOUNTANT'S COMPILATION REPORT

To: the management

The financial statements of Stichting Duchenne Data Foundation at Bergen op Zoom have been compiled by us using the information provided by you. The financial statements comprise the balance sheet as at December 31, 2021 and the profit and loss account for the year 2021 with the accompanying explanatory notes. These notes include a summary of the accounting policies which have been applied.

This compilation engagement has been performed by us in accordance with Dutch law, including the Dutch Standard 4410, "Compilation engagements", which is applicable to accountants. The standard requires us to assist you in the preparation and presentation of the financial statements in accordance with Part 9 of Book 2 of the Civil Code. To this end we have applied our professional expertise in accounting and financial reporting.

In a compilation engagement, you are responsible for ensuring that you provide us with all relevant information and that this information is correct. Therefore, we have conducted our work, in accordance with the applicable regulations, on the assumption that you have fulfilled your responsibility. To conclude our work, we have read the financial statements as a whole to consider whether the financial statements as presented correspond with our understanding of Stichting Duchenne Data Foundation. We have not performed any audit or review procedures which would enable us to express an opinion or a conclusion as to the fair presentation of the financial statements.

During this engagement we have complied with the relevant ethical requirements prescribed by the "Verordening Gedrags- en Beroepsregels Accountants" (VGBA). You and other users of these financial statements may therefore assume that we have conducted the engagement in a professional, competent and objective manner and with due care and integrity and that we will treat all information provided to us as confidential.

For further information on the nature and scope of a compilation engagement and the VGBA we refer you to www.nba.nl/uitleg-samenstellingsverklaring.

3 RESULTS

3.1 Development of income and expenses

The results for 2021 amounts negatief € 5,417 to € 80,661 for 2020. The results for both years can be summarized as follows:

	2021	2020
	€	€
Income		
Income from individuals	125,500	-
Subsidies	-	66,549
Other income	147,400	177,400
Gross margin	272,900	243,949
Expenditure		
Expenditure on activities	159,594	143,753
Office expenses	80,145	3,677
Publicity expenses	252	296
General expenses	38,053	15,562
Sum of expenses	278,044	163,288
Resultaat	-5,144	80,661
Financial income and expenses		
Interest and similar expenses	-273	-
Result	-5,417	80,661

4 FINANCIAL POSITION

The balance sheet can be summarized as follows:

	12/31/2021		12/31/2020	
	€	€	€	€
Long term funds:				
Reserves and funds		433,729		439,146
		<u>433,729</u>		<u>439,146</u>
This amount is applied as follows:				
Receivables, prepayments and accrued income	90,138		78,862	
Cash and cash equivalents	<u>379,539</u>		<u>365,393</u>	
		469,677		444,255
Debit: Short-term debt		35,948		5,109
Working capital		<u>433,729</u>		<u>439,146</u>

Yours sincerely,
Stolwijk Registeraccountants & Belastingadviseurs B.V.

I.M. van Lexmond AA

MANAGEMENT BOARD REPORT

Purpose of this document

The purpose of this Board Management Report is to present and summarize the activities performed by the Board and employees of the Duchenne Data Foundation (DDF) in 2021. This report will serve as a communication tool to update the current Board members on the work and activities performed and completed in the previous year.

Composition and roles of Board members

The board members are:

- Paliouras, G. (Chair and Director R&D) since 01/01/2020
- Franken - Verbeek, M.J.F. (Secretary) since 15/01/2019
- Fischer, R.K. (member) – from 16/04/2020 until 30/09/2021
- Schreur, R. (Director of Finance and Business Development) – since 06/12/2021
- Bayley, K. (Director of Community Empowerment) – From 25/05/2021 to 20/07/2022
- Thakrar, S. (Director of Data Services) – From 01/05/2021 until 30/07/2021
- Ajaikumar, BS. (Director of Clinical Programs) – since 01/10/2021

Mission and Vision

Mission and vision

DDF believes that patients should be able to own, control, and share their data. Therefore, DDF fosters multi-source data connection so people living with dystrophinopathies can live their lives to the fullest. By building the missing link between various sources of data, evidence is generated to optimize R&D and care practices.

Our goal is to accelerate the pathway to the development of innovative therapies, improve care and best practices, reduce misinformation and promote participation in the global dystrophinopathy community.

Our mission is to connect the fragmented data in the field of dystrophinopathies and test innovative solutions, scaling them to make a global impact.

Our vision is to bring data to life to improve the world of dystrophinopathies.

Strategy

Strategic direction

The strategic direction of DDF is built around 4 key pillars:

1. Research & Development
2. Standards of Care & Quality of Life
3. Education & Capacity Building
4. Data Equity & Access

Research & Development

DDF connects data to generate new evidence for more efficient and faster research in therapy development and care. The aim is to create an environment of dystrophinopathy data from various sources and locations, following the strict standards of data governance and ['FAIR'](#) principles. This evidence will inform the development of best care practices and therapies and support and inform regulatory and policy processes. The organization will enable the safe exchange of data and information to inform all areas of research and stakeholders.

Standards of Care & Quality of Life

DDF strives for all people living with dystrophinopathies around the world to have access to the latest standards of care and the best quality of life. This includes early diagnosis and surveillance alongside quality-of-life initiatives. This will be achieved by collecting and analyzing data related to patient needs and preferences and connecting patients with the services they need.

Education & Training

DDF provides training to all stakeholders. The goal is to empower the global dystrophinopathy community voice to ensure research is patient and family-led and centered. The Duchenne Data Foundation will work alongside the World Duchenne Organization to facilitate the exchange of timely, evidence-based, and accurate information so all stakeholders can make informed decisions. This includes, but is not limited to, training on clinical trials and research, and patients being in control of their data.

Data Governance & Access

People should be able to own, control, and share their data. DDF advocates for people living with dystrophinopathies to achieve this. At the same time, the dystrophinopathy community should be able to benefit from the insights of the data.

Activities performed in 2021

1. Administration and management activities

- The goals, mission, and vision of the Duchenne Data Foundation for 2022 – 2025 have been set and applied.
- New Standard Operating Procedures have been introduced. The financial procedure, the personnel management procedure, and the Board management procedure are currently in effect to organize and oversee all processes.
- Key Performance Indicators have been developed to evaluate the efficiency of all DDF projects and actions. The document is under review.
- ClickUp, a project and organization management tool were deployed successfully and used by all the members of the organization.
- The Information Security Management System Manual was developed and implemented.
- New [full-time personnel](#) were hired to support the activities of DDF.

Evaluation: New organizational procedures and administrative/management processes were implemented, improving the operation of the organization.

2. Communication/dissemination activities

- A new [website](#), offering an optimal user experience, was developed, and deployed.
- A brand guide was created and deployed to promote coherence in the communication materials of DDF.

Outcomes: In 2021, we worked on creating the identity and image of DDF to communicate and disseminate better with our audience. We noticed an increase in the number of followers on social media (1 000 followers in total for Facebook, Twitter, and LinkedIn) as well as an almost double percentage of subscribers in our Newsletter.

3. Projects

Internal DDF Projects

- [Duchenne Data Repository](#)

The Duchenne Data Repository (DDR) is a storage location that can host a range of data types, including pre-clinical, natural history, clinical trials, patient-generated health data, and others. DDR aims to facilitate the findability of dystrophinopathy data stored in different locations through the development of metadata catalogs. DDR promotes FAIR data principles and is compliant with all GDPR, security, data protection, and privacy standards and policies.

Outcomes: New functionalities based on BIND project partners needs/preferences were developed and integrated in the database stored in DDR. DDR also received the first datasets from the BIND partners. Discussions with external public repositories started for future DMD/BMD data connections.

Project Status: Ongoing

Evaluation: An advanced version of the architecture and functionalities of the DDR was planned for 2022.

- [Duchenne Map](#)

Duchenne Map is an online platform connecting Duchenne/Becker Muscular Dystrophy (DMD/BMD) families with their local patient organizations, healthcare providers, care centers, researchers, research institutions, and pharmaceutical companies. Duchenne Map offers a secure and inclusive platform where all stakeholders share reliable information.

Outcomes: The [Clinical Trial filter function](#) was deployed successfully. Registered patient organizations (15) can search clinical trials based on criteria such as location, age, ambulation status, and corticosteroid use. Pharmaceutical companies registration was launched.

Project Status: Ongoing. A concrete project plan was developed to plan and monitor future tasks.

Evaluation: 35 new patient organizations were registered on the Map.

European Projects

- [BIND Project](#)

This EU-funded project connects 19 partners and aims to address learning and behavioral issues in DMD/BMD.

Outcomes: A dedicated database, stored in DDR, was developed, and serves as the central storage of the newly generated BIND datasets. The first datasets of the project were received and stored.

Project Status: Ongoing

Evaluation: DDF in collaboration with the EBRAINS Research Infrastructure (in-kind contribution) and LUMC (project partner) is responsible for the organization of FAIR workshops and implementation of FAIR processes for the BIND datasets. Security, data protection and data privacy policies are in place for the database and monitored continuously by the DDF Information Security Officer. Connection with the EBRAINS database is planned for 2022-2023.

- [EURO-NMD Registry Hub](#)

The general objective of this EU-funded project is to build a unified Registry Hub for neuromuscular diseases, including undiagnosed patients, and connect with the existing registries.

Outcomes: DDF has significantly contributed in the project management deliverables until a project manager was hired, as well as in the communication/dissemination activities. DDF also participated in technical working group discussions regarding the development of the software used for the Registry

Hub, and FAIR processes for future interoperability with pilot registries during the lifetime of the project.

Project Status: Ongoing

Evaluation: DDF will be actively participating in the evaluation of data quality and completeness of the data stored in the EURO-NMD Registry, the FAIRification and interoperability processes, as well as dissemination and communication activities.

Projects with pharmaceutical companies

- **Duchenne Patient Pathway Project**

The Duchenne Patient Pathway Project was a collaboration with Roche. The project explored how caregivers and patient organizations perceive the patient pathway in pre-gene therapy era (i.e., the needs, and the gaps in different countries) and how the availability of gene therapy impacts each of these components.

Outcomes: DDF supported Roche with the engagement of patient organizations and patient caregivers to collect the necessary information from the participating countries: Italy, Brazil, Canada, and France.

Project Status: Completed.

Evaluation: The project provided preliminary results regarding common challenges, gaps and needs faced by the participating countries and provided useful information on the emotional burden and potential solutions. However, the number of participants was limited and it was proposed to repeat the survey to a larger study population.

Projects in collaboration with the World Duchenne Organization

- [DMD Emergency Program](#)

The DMD Emergency Program aims to support local patient organizations and communities dealing with unexpected emergencies.

Outcomes: Support was offered for the Lebanon emergency, after the Beirut explosion. Medical equipment was donated to families with DMD/BMD children.

Project Status: Ongoing

Evaluation: New funding was received for future emergencies.

- [Duchenne and Becker Digital Program](#)

The program consists of a series of digital events and webinars where participants take a deep dive into topics relevant to all patients and patient organizations. The main goal is to educate DMD/BMD advocates by analyzing topics that are of interest to the community. The webinars were attended by a limited number of participants, to allow sharing of experiences and encourage interaction.

Novelties: In 2021, 2 webinars were organized. The first one was dedicated to communication and [how to build an on and offline presence](#). The second one was an experience sharing from different patient organizations, on [how to build a community](#).

Project Status: Ongoing

Evaluation: The two webinars were followed by more than 30 patient advocates and viewed by more than 60 people on YouTube.

- [Duchenne CAB](#)

The Duchenne CAB is an international board consisting of independent, autonomous, and trained patient representatives. The goal is to provide its collective knowledge and expertise to accelerate research, development, clinical trials, and access to effective treatments for DMD and BMD worldwide.

Outcomes: The Duchenne CAB held 14 meetings with 7 different companies. The [reports](#) from these meetings are available.

Project Status: Ongoing

Evaluation: The Duchenne CAB continues to offer meaningful support to companies to promote better treatment and patient-centered research.

- [Social Duchenne](#)

Social Duchenne is an international project aiming to highlight and raise awareness of psychosocial issues in DMD/BMD. Qualitative interviews are performed to uncover the psychological needs and challenges of DMD/BMD families all over the world.

Outcomes: A survey about the daily life of people living with DMD/BMD was conducted and results were collected from 30 different countries. The survey aimed to collect the most important factors that limit and burden the everyday life of people living with DMD/BMD.

Project Status: Ongoing

Evaluation: Results of the survey are available [here](#).

- [Duchenne Patient Academy](#)

Duchenne Patient Academy is a training program to enhance patient advocacy and education, and drive the international advocacy agenda. Participants benefit from in-depth training on community needs, company updates, expert panel sessions, and network building.

Outcomes: [Duchenne Patient Academy](#) 2021 took place online in 5 consecutive days. Each day focused on a specific topic, based on questions from the community. The Board of Directors actively participated in the Duchenne Patient Academy 2021. Specifically, they presented and moderated sessions on clinical trials and the importance of data from a clinical and research perspective.

Project Status: Ongoing

Evaluation: The Duchenne Patient Academy was followed by more than 75 participants from over 40 countries. An evaluation form was completed by the participants after the training, highlighting new topics of interest to the community for future trainings.

Conclusions

In 2021, DDF participated and co-led multiple international projects to the benefit of the DMD community. These projects advanced successfully and addressed several aspects of interest to the DMD/BMD community, including social burden and quality of life, optimal sharing of research and clinical data, training of patient advocates, and creation of useful applications to provide access to relevant information (clinical trials, patient organizations). With the addition of new personnel and Board members, DDF is advancing and continuously enriching its activities to improve the world of dystrophinopathies.

Stichting Duchenne Data Foundation, Bergen op Zoom

1 BALANCE SHEET AS AT DECEMBER 31, 2021
(after result appropriation)

	December 31, 2021		December 31, 2020	
	€	€	€	€
ACTIVA				
CURRENT ASSETS				
Receivables, prepayments and accrued income	(1)			
Account receivable	75,000		77,900	
Other receivables, deferred assets	15,138		962	
		90,138		78,862
Cash and cash equivalents	(2)			
		379,539		365,393
		469,677		444,255

	December 31, 2021		December 31, 2020	
	€	€	€	€
PASSIVA				
RESERVES AND FUNDS	(3)			
Unrestricted funds, designated	250,000		250,000	
Designated reserve projects - BIND	32,162		48,820	
Unrestricted funds, general	151,567		140,326	
		433,729		439,146
CURRENT LIABILITIES	(4)			
Account payable	13,462		5,000	
Taxes and social securities	18,225		-	
Other liabilities and Accruals and deferred income	4,261		109	
		35,948		5,109
		<u>469,677</u>		<u>444,255</u>

2 STATEMENT OF THE FINANCIAL ACTIVITIES OVER 2021

	Balance 2021	Balance 2020
	€	€
Income		
Income from individuals	(5) 125,500	-
Subsidies	(6) -	66,549
Other income	(7) 147,400	177,400
Sum of income	272,900	243,949
Expenses		
Expenditure on activities	159,594	143,753
Costs of support		
Office expenses	(10) 80,145	3,677
Publicity expenses	(11) 252	296
General expenses	(12) 38,053	15,562
	118,450	19,535
Balance before financial income and expense	-5,144	80,661
Financial income and expenses	(13) -273	-
Result	-5,417	80,661
Appropriation of the results		
Designated reserve projects - BIND	-16,658	48,820
Unrestricted funds, general	11,241	31,841
	-5,417	80,661

3 NOTES TO THE FINANCIAL STATEMENTS

GENERAL

Activities

The activities of Stichting Duchenne Data Foundation (CoC file 64601188), with registered offices in Bergen op Zoom, mainly consist of the following: The worldwide collaboration between Duchenne Parent Organizations in order to improve the understanding of the course of disease process, the effect of treatment methods, the needs and preferences and all other aspects of all those affected by Duchenne muscular dystrophy (DMD and BMD).

Registered office, legal form and registration number at the chamber of commerce

The registered and actual address of Stichting Duchenne Data Foundation is Warmoesdreef 10, 4614 HC, in Bergen op Zoom of business and is registered at the chamber of commerce under number 64601188.

Estimates

In applying the principles and policies for drawing up the financial statements, the directors of Stichting Duchenne Data Foundation make different estimates and judgments that may be essential to the amounts disclosed in the financial statements. If it is necessary in order to provide the transparency required under Book 2, article 362, paragraph 1, the nature of these estimates and judgments, including related assumptions, is disclosed in the notes to the relevant financial statement item.

GENERAL ACCOUNTING PRINCIPLES FOR THE PREPARATION OF THE ANNUAL ACCOUNTS

The annual accounts have been prepared in accordance with the guidelines for annual reporting for small organisations without profit motive (Rjk C1). These are in line with the requirements for small legal entities that fall under Title 9 Book 2 of the Dutch Civil Code.

Valuation of assets and liabilities and determination of the result takes place under the historical cost convention. Unless presented otherwise at the relevant principle for the specific balance sheet item, assets and liabilities are presented at nominal value.

Income and expenses are allocated to the year to which they relate. Profits are only included insofar as they have been realized on the balance sheet date. Liabilities and possible losses that originate before the end of the reporting year are taken into account if they have become known before the preparation of the annual accounts.

ACCOUNTING PRINCIPLES APPLIED TO THE VALUATION OF ASSETS AND LIABILITIES

General

Securities

Upon initial recognition the receivables on and loans to participations and other receivables are valued at fair value and then valued at amortised cost, which equals the face value, after deduction of any provisions. The fair value and amortised cost equal the face value. Any provisions for the risk of doubtful debts are deducted. These provisions are determined based on individual assessment of the receivables.

Cash and cash equivalents

The cash is valued at face value. If cash equivalents are not freely disposable, then this has been taken into account in the valuation.

Reserves en fondsen

Unrestricted funds, designated

The Unrestricted funds, designated are reserves with a more limited spending option, whereby the limitation is made by the board. The nature of the limitation is explained later.

Current liabilities

On initial recognition current liabilities are recognised at fair value. After initial recognition current liabilities are recognised at the amortised cost price, being the amount received taking into account premiums or discounts and minus transaction costs. This is usually the nominal value.

ACCOUNTING PRINCIPLES FOR THE DETERMINATION OF THE RESULT

Determination of the result

The result is determined based upon the difference between the nett income and the costs and other expenses taking into account the aforementioned valuation principles.

Income from individuals

Income from private individuals and private companies are general donations for the foundation

Subsidies

Operating subsidies are recorded as income in the profit and loss account in the year in which the subsidised costs were incurred or income was lost or when there was a subsidised operating deficit.

Income is recognised when it is probable that it will be received.

Subsidies related to investments in tangible fixed assets are deducted from the asset to which they relate and recorded in the profit and loss account as part of the amortisation costs.

Expenditure on activities

The expenditure on activities consists of the cost directly related to the activities.

Gross margin

The gross operating profit and loss comprises net turnover, the changes in inventories of finished goods and work in progress, work performed by the entity and capitalised, other operating income, cost price and cost of outsourced work and other external charges.

Expenses general

Costs are determined on a historical basis and are attributed to the reporting year to which they relate.

Employee expenses

The benefits payable to personnel are recorded in the profit and loss account on the basis of the employment conditions.

Financial income and expenses

Interest income and interest expenses

Interest income and expenses are recognised on a pro rata basis, taking account of the effective interest rate of the assets and liabilities to which they relate. In accounting for interest expenses, the recognised transaction expenses for loans received are taken into consideration.

4 NOTES TO THE BALANCE SHEET AS OF DECEMBER 31, 2021

ASSETS

1. Receivables, prepayments and accrued income

	<u>12/31/2021</u>	<u>12/31/2020</u>
	€	€
<i>Account receivable</i>		
Account receivable	76,000	77,900
Provision for accounts receivable	-1,000	-
	<u>75,000</u>	<u>77,900</u>
 <i>Other receivables and prepayments</i>		
Current account WDO	14,176	-
Insurance	962	962
	<u>15,138</u>	<u>962</u>
 2. Cash and cash equivalents		
NL75ABNA0620549920	<u>379,539</u>	<u>365,393</u>

The liquid resources are valued at nominal value. The liquid resources available as at December 31, 2021 are freely available to the Stichting Duchenne Data Foundation.

EQUITY AND LIABILITIES

	<u>12/31/2021</u>	<u>12/31/2020</u>
	€	€
3. Reserves and funds		
Unrestricted funds, designated	250,000	250,000
Designated reserve projects - BIND	32,162	48,820
Unrestricted funds, general	151,567	140,326
	<u>433,729</u>	<u>439,146</u>
Unrestricted funds, designated		
Selfinitiated Projects	100,000	100,000
Continuity reserves	150,000	150,000
	<u>250,000</u>	<u>250,000</u>
	<u>2021</u>	<u>2020</u>
	€	€
<i>Selfinitiated Projects</i>		
Carrying amount as of January 1	100,000	100,000
Carrying amount as of December 31	<u>100,000</u>	<u>100,000</u>
<i>Continuity reserves</i>		
Carrying amount as of January 1	150,000	150,000
Carrying amount as of December 31	<u>150,000</u>	<u>150,000</u>
<i>Designated reserve projects - BIND</i>		
Carrying amount as of January 1	48,820	-
Result allocation	-16,658	48,820
Carrying amount as of December 31	<u>32,162</u>	<u>48,820</u>
<i>Unrestricted funds, general</i>		
Carrying amount as of January 1	140,326	108,485
Allocation of financial year nett result	11,241	31,841
Carrying amount as of December 31	<u>151,567</u>	<u>140,326</u>

4. Current liabilities

	<u>12/31/2021</u>	<u>12/31/2020</u>
	€	€
<i>Account payable</i>		
Account payable	<u>13,462</u>	<u>5,000</u>
<i>Taxes and social securities</i>		
VAT	17,642	-
Pay-roll tax	<u>583</u>	-
	<u>18,225</u>	-
<i>VAT</i>		
VAT supplementation 2021	11,865	-
VAT supplementation 2020	<u>5,777</u>	-
	<u>17,642</u>	-
<i>Pay-roll tax</i>		
Pay-roll tax last period	<u>583</u>	-
<i>Other liabilities and Accruals and deferred income</i>		
Audit costs	3,000	-
Nett income	-	109
Invoices to receive	<u>1,261</u>	-
	<u>4,261</u>	<u>109</u>

5 NOTES TO THE STATEMENT OF FINANCIAL ACTIVITIES 2021

	Balance 2021	Balance 2020
	€	€
5. Income from individuals		
Donations	125,500	-
6. Subsidies		
European Commission subsidy BIND	-	66,549
7. Other income		
Income Community Advisory Board	97,400	61,400
Income Patient Academy	-	16,000
Income Emergency Programm	50,000	-
Income Digital D&B Program	-	100,000
	<u>147,400</u>	<u>177,400</u>
8. Expenditure on activities		
Costs of congress and seminars	85	1,945
Costs of Community Advisory Board	30,007	29,382
Costs of MAP	7,997	25,277
Costs of Patient Academy	30,435	17,158
Costs of Psycho Project	11,709	15,591
Costs of Meeting Rome	-	271
Costs of EURO NMD	1,168	2,890
Costs of Digital D&B Program	10,411	10,000
Costs of DDF Repository	10,739	23,510
Cost of BIND	16,658	17,729
Costs of FAIR	19,532	-
Costs of WDAD	853	-
Costs of Emergency Programm	20,000	-
	<u>159,594</u>	<u>143,753</u>
9. Employee expenses		
Wages and salaries	13,201	12,943
Social security charges	2,340	2,995
Other personnel costs	-15,541	-15,938
	<u>-</u>	<u>-</u>
<i>Wages and salaries</i>		
Gross wages	12,223	11,984
Gross holidaypay	978	959
	<u>13,201</u>	<u>12,943</u>
<i>Social security charges</i>		
Other social charges	2,340	2,995
	<u>2,340</u>	<u>2,995</u>

Stichting Duchenne Data Foundation, Bergen op Zoom

	Balance 2021	Balance 2020
	€	€
<i>Other personnel costs</i>		
Travelling expenses	894	894
Allocated labour costs Patient Academy	-16,435	-16,832
	<u>-15,541</u>	<u>-15,938</u>
Staff		
During 2021 1 employee was employed on a full-time basis.(2020: 1)		
Other operating expenses		
10. Office expenses		
Office supplies	-	87
Automation costs	79,970	3,590
Contributions and subscriptions	175	-
	<u>80,145</u>	<u>3,677</u>
11. Publicity expenses		
Publicity and advertisement	252	296
12. General expenses		
Audit costs	8,100	7,404
Auditcosts previous years	3,401	3,824
consultancy fees	-	1,577
Insurance costs	1,011	977
Bank costs	432	1,806
Amortisation of doubtful debtors	1,000	-
Non-deductible VAT	23,566	-
Other general expenses	543	-26
	<u>38,053</u>	<u>15,562</u>
13. Financial income and expenses		
Interest and similar expenses	-273	-
<i>Interest and similar expenses</i>		
Other interest payable	-273	-

OTHER INFORMATION

OTHER INFORMATION

1 Audit

your company has utilized the exemption from an audit by virtue of art. 2:396, paragraph 7 of the Dutch Civil Code.

2 Recognition of the loss for 2021

The board of directors proposes to add the 2021 result to the other reserves for an amount of € 5,417. The General Meeting of Shareholders will be asked to approve the appropriation of the 2021 result, this proposition is already recognised in the financial statements.